Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 1
2004 1
2005 2
2007 2
2009 1
2010 2
2011 2
2012 1
2013 3
2014 2
2015 2
2016 2
2017 3
2018 2
2021 2
2022 2
2023 1
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

29 results

Results by year

Filters applied: . Clear all
Page 1
Pomalidomide and dexamethasone until progression after first salvage therapy in multiple myeloma.
Garderet L, Kuhnowski F, Berge B, Roussel M, Devlamynck L, Petillon MO, Escoffre-Barbe M, Lafon I, Facon T, Leleu X, Karlin L, Perrot A, Stoppa AM, Royer B, Chaleteix C, Tiab M, Araujo C, Lenain P, Macro M, Belhadj K, Ikhlef S, Hulin C, Loiseau HA, Attal M, Moreau P. Garderet L, et al. Among authors: chaleteix c. Br J Haematol. 2023 Jun;201(6):1103-1115. doi: 10.1111/bjh.18772. Epub 2023 Mar 27. Br J Haematol. 2023. PMID: 36974007
Characteristics and incidence of infections in patients with multiple myeloma treated by bispecific antibodies: a national retrospective study on the behalf of G2I and Intergroupe Francophone du Myélome.
Jourdes A, Cellerin E, Touzeau C, Harel S, Denis B, Escure G, Faure E, Jamard S, Danion F, Sonntag C, Ader F, Karlin L, Soueges S, Cazelles C, de La Porte des Vaux C, Frenzel L, Lanternier F, Brousse X, Cazaubiel T, Berger P, Collignon A, Blot M, Pieragostini A, Charles M, Chaleteix C, Redor A, Roland V, Cartau T, Macro M, Chalopin T, Vallet N, Perrot A, Martin-Blondel G; G2I and the IFM networks. Jourdes A, et al. Among authors: chaleteix c. Clin Microbiol Infect. 2024 Mar 1:S1198-743X(24)00098-3. doi: 10.1016/j.cmi.2024.02.023. Online ahead of print. Clin Microbiol Infect. 2024. PMID: 38432433 Free article.
[Pomalidomide for multiple myeloma].
Dougé A, Lemal R, Chaleteix C. Dougé A, et al. Among authors: chaleteix c. Bull Cancer. 2017 Sep;104(9):707-713. doi: 10.1016/j.bulcan.2017.04.005. Epub 2017 Jun 2. Bull Cancer. 2017. PMID: 28583668 French.
Pomalidomide, cyclophosphamide, and dexamethasone for relapsed multiple myeloma.
Garderet L, Kuhnowski F, Berge B, Roussel M, Escoffre-Barbe M, Lafon I, Facon T, Leleu X, Karlin L, Perrot A, Moreau P, Marit G, Stoppa AM, Royer B, Chaleteix C, Tiab M, Araujo C, Lenain P, Macro M, Voog E, Benboubker L, Allangba O, Jourdan E, Orsini-Piocelle F, Brechignac S, Eveillard JR, Belhadj K, Wetterwald M, Pegourie B, Jaccard A, Eisenmann JC, Glaisner S, Mohty M, Hulin C, Loiseau HA, Mathiot C, Attal M. Garderet L, et al. Among authors: chaleteix c. Blood. 2018 Dec 13;132(24):2555-2563. doi: 10.1182/blood-2018-07-863829. Epub 2018 Oct 3. Blood. 2018. PMID: 30282798 Free article. Clinical Trial.
Cerebral aspergillosis in a patient on ibrutinib therapy.
Creuzet E, Nourrisson C, Chaleteix C, Poirier P, Moniot M. Creuzet E, et al. Among authors: chaleteix c. Br J Haematol. 2021 Jun;193(6):1025. doi: 10.1111/bjh.17354. Epub 2021 Mar 21. Br J Haematol. 2021. PMID: 33748950 No abstract available.
Bortezomib and high-dose melphalan conditioning regimen in frontline multiple myeloma: an IFM randomized phase 3 study.
Roussel M, Lauwers-Cances V, Macro M, Leleu X, Royer B, Hulin C, Karlin L, Perrot A, Touzeau C, Chrétien ML, Rigaudeau S, Dib M, Nicolas-Virelizier E, Escoffre-Barbe M, Belhadj K, Mariette C, Stoppa AM, Araujo C, Doyen C, Fontan J, Kolb B, Garderet L, Brechignac S, Malfuson JV, Jaccard A, Lenain P, Borel C, Hebraud B, Benbrahim O, Dorvaux V, Manier S, Augeul-Meunier K, Vekemans MC, Randriamalala E, Chaoui D, Caers J, Chaleteix C, Benboubker L, Vincent L, Glaisner S, Zunic P, Slama B, Eveillard JR, Humbrecht-Kraut C, Morel V, Mineur P, Eisenmann JC, Demarquette H, Richez V, Vignon M, Caillot D, Facon T, Moreau P, Colin AL, Olivier P, Wuilleme S, Avet-Loiseau H, Corre J, Attal M. Roussel M, et al. Among authors: chaleteix c. Blood. 2022 May 5;139(18):2747-2757. doi: 10.1182/blood.2021014635. Blood. 2022. PMID: 35511184 Free article. Clinical Trial.
Relation between auditory difficulties and bortezomib-induced peripheral neuropathy in multiple myeloma: a single-center cross-sectional study.
Giraudet F, Selvy M, Kerckhove N, Pereira B, Barreau F, Nguyen D, Busserolles J, Cabrespine A, Chaleteix C, Soubrier M, Bay JO, Lemal R, Balayssac D. Giraudet F, et al. Among authors: chaleteix c. Eur Arch Otorhinolaryngol. 2022 Apr;279(4):2197-2201. doi: 10.1007/s00405-021-07234-1. Epub 2022 Jan 31. Eur Arch Otorhinolaryngol. 2022. PMID: 35098333
Prevalence of Chemotherapy-Induced Peripheral Neuropathy in Multiple Myeloma Patients and its Impact on Quality of Life: A Single Center Cross-Sectional Study.
Selvy M, Kerckhove N, Pereira B, Barreau F, Nguyen D, Busserolles J, Giraudet F, Cabrespine A, Chaleteix C, Soubrier M, Bay JO, Lemal R, Balayssac D. Selvy M, et al. Among authors: chaleteix c. Front Pharmacol. 2021 Apr 22;12:637593. doi: 10.3389/fphar.2021.637593. eCollection 2021. Front Pharmacol. 2021. PMID: 33967771 Free PMC article.
29 results